MACTIDE peptide

MACTIDE peptide

• Handling and Storage of Synthetic Peptides
• Material Safety Data Sheets (MSDS)

Batch to batch variation of the purity

H-GC*TKSIPPIC*SPGAK-OH (disulfide bond: Cys2-Cys10)

H-Gly-Cys-Thr-Lys-Ser-Ile-Pro-Pro-Ile-Cys-Ser-Pro-Gly-Ala-Lys-OH (disulfide bond: Cys2-Cys10)

15

95.38%

C₆₂H₁₀₅N₁₇O₁₉S₂

1456.72

Synthetic

Powder

MACTIDE is an engineered CD206-targeting peptide designed to enhance the affinity and proteolytic stability of its predecessor, mUNO. By incorporating a trypsin inhibitor loop from Sunflower Trypsin Inhibitor-1 (SFTI-1), MACTIDE adopts a constrained structure, improving its binding to CD206 (15-fold lower KD than mUNO) and extending its half-life in tumor environments (5-fold increase). It effectively homes to CD206+ tumor-associated macrophages (TAMs) in triple-negative breast cancer (TNBC) models via intravenous, intraperitoneal, or oral administration, with minimal liver accumulation.

In preclinical models, MACTIDE-V slows primary tumor growth, reduces lung metastases, and enhances infiltration of cytotoxic lymphocytes (CD8+ T cells, NK cells) while suppressing immunosuppressive markers (PD-1). Its oral bioavailability, low toxicity, and ability to modulate TAMs without irradiation highlight its potential as a novel immunotherapy for breast cancer.

Normally, this peptide will be delivered in lyophilized form and should be stored in a freezer at or below -20 °C. For more details, please refer to the manual: Handling and Storage of Synthetic Peptides

• Lepland A, Peranzoni E, Haljasorg U, Asciutto EK, Crespí-Amer M, Modesti L, Kilk K, Lombardia M, Acosta G, Royo M, Peterson P, Marigo I, Teesalu T, Scodeller P. Peptide-Drug Conjugate for Therapeutic Reprogramming of Tumor-Associated Macrophages in Breast Cancer. Adv Sci (Weinh). 2025 Mar;12(10):e2410288. doi: 10.1002/advs.202410288. Epub 2025 Jan 22. PMID: 39840532; PMCID: PMC11904948.

Trifluoroacetic acid (TFA) has a significant impact on peptides due to its role in the peptide synthesis process.

TFA is essential for the protonation of peptides that lack basic amino acids such as Arginine (Arg), Histidine (His), and Lysine (Lys), or ones that have blocked N-termini. As a result, peptides often contain TFA salts in the final product.

TFA residues, when present in custom peptides, can cause unpredictable fluctuations in experimental data. At a nanomolar (nM) level, TFA can influence cell experiments, hindering cell growth at low concentrations (as low as 10 nM) and promoting it at higher doses (0.5–7.0 mM). It can also serve as an allosteric regulator on the GlyR of glycine receptors, thereby increasing receptor activity at lower glycine concentrations.

In an in vivo setting, TFA can trifluoroacetylate amino groups in proteins and phospholipids, inducing potentially unwanted antibody responses. Moreover, TFA can impact structure studies as it affects spectrum absorption.